Epidemiology and Research Unit, E. Wolfson Medical Center, Holon, Israel.
Nephron Clin Pract. 2009;113(3):c169-76. doi: 10.1159/000232598. Epub 2009 Aug 12.
BACKGROUND/AIMS: The present study was designed to investigate the short-term safety and efficacy of topical application with body lotion enriched with minerals from the Dead Sea versus 2 different placebo treatments in reducing symptoms of uremic pruritus.
In this single-center, randomized, double placebo-controlled clinical trial, 78 hemodialysis patients with self-reported uremic pruritus were randomized to twice-daily topical treatment with body lotion enriched with minerals from the Dead Sea (DS) or to each of 2 types of placebo: (1) lotion with no Dead Sea minerals but otherwise identical to DS (P1) or (2) lotion with no active ingredients (P2). Symptoms of uremic pruritus (itching, dryness, peeling, tightness) were evaluated at baseline and 2 weeks (14 days) after treatment intervention using a 5-point Likert scale.
Following treatment, significant differences in symptom severity scores between DS and P1 and, separately, between group DS and P2, were not detected. Additionally, when DS was compared to the combined placebo groups (P1 and P2 together), significant post-treatment differences in symptom severity scores were not observed. Symptoms were less severe post-treatment regardless of treatment assignment.
DS was not superior to either of the placebo treatments in the symptomatic relief of uremic pruritus.
背景/目的:本研究旨在探讨富含死海矿物质的身体乳液局部应用与两种不同安慰剂治疗在减轻尿毒症瘙痒症状方面的短期安全性和疗效。
在这项单中心、随机、双安慰剂对照临床试验中,78 名有尿毒症瘙痒症状报告的血液透析患者被随机分为两组,每天两次局部应用富含死海矿物质的身体乳液(DS)或两种安慰剂之一:(1)不含死海矿物质但其他方面与 DS 相同的乳液(P1)或(2)不含活性成分的乳液(P2)。使用 5 分制 Likert 量表在基线和治疗干预后 2 周(14 天)评估尿毒症瘙痒症状(瘙痒、干燥、脱皮、紧绷)。
治疗后,DS 与 P1 之间以及 DS 与 P2 之间的症状严重程度评分差异无统计学意义。此外,将 DS 与联合安慰剂组(P1 和 P2 一起)进行比较时,治疗后症状严重程度评分也没有显著差异。无论治疗分配如何,治疗后症状均有所缓解。
DS 并不优于任何一种安慰剂治疗在缓解尿毒症瘙痒症状方面的效果。